Nuvectra (NVTR) 10-Q 2 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Apr. 26, 2018
Document Information [Line Items]
Entity Registrant Name	Nuvectra Corp
Entity Central Index Key	1,648,893
Trading Symbol	nvtr
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		14,153,305
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 53,851	$ 28,165
Trade accounts receivable, net of allowance for doubtful accounts of $417 in 2018 and 2017	9,080	10,875
Inventories	4,478	4,978
Prepaid expenses and other current assets	917	1,011
Total current assets	68,326	45,029
Property, plant and equipment, net	6,036	6,219
Intangible assets, net	1,353	1,428
Goodwill	38,182	38,182
Other long-term assets	109	245
Total assets	114,006	91,103
Current liabilities:
Accounts payable	3,178	2,043
Accrued liabilities	6,438	8,827
Accrued compensation	2,798	4,392
Short-term debt		789
Total current liabilities	12,414	16,051
Other long-term liabilities	660	993
Long-term debt, net	38,409	25,886
Total liabilities	51,483	42,930
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, $0.001 par value, 100,000,000 shares authorized; 14,147,446 and 10,849,385 shares issued and outstanding in 2018 and 2017, respectively	14	11
Additional paid-in capital	150,878	125,999
Accumulated other comprehensive loss		(1)
Accumulated deficit	(88,369)	(77,836)
Total stockholders’ equity	62,523	48,173
Total liabilities and stockholders’ equity	$ 114,006	$ 91,103

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Trade accounts receivable, allowance for doubtful accounts	$ 417	$ 417
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	14,147,446	10,849,385
Common stock, shares outstanding (in shares)	14,147,446	10,849,385

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Sales:
Sales	$ 10,574	$ 5,040
Cost of sales:
Cost of sales	4,808	2,411
Gross profit	5,766	2,629
Operating expenses:
Selling, general and administrative expenses	12,133	10,805
Research, development and engineering costs, net	3,280	4,373
Total operating expenses	15,413	15,178
Operating loss	(9,647)	(12,549)
Interest expense, net	850	370
Other expense, net	23	203
Loss before provision for income taxes	(10,520)	(13,122)
Provision for income taxes	13
Net loss	$ (10,533)	$ (13,122)
Basic and diluted net loss per share (in dollars per share)	$ (0.84)	$ (1.27)
Basic and diluted weighted average shares outstanding (in shares)	12,509	10,335
Product [Member]
Sales:
Sales	$ 10,118	$ 4,588
Cost of sales:
Cost of sales	4,454	2,101
Service [Member]
Sales:
Sales	456	452
Cost of sales:
Cost of sales	$ 354	$ 310

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (10,533)	$ (13,122)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for uncollectible accounts		44
Write-downs of excess and obsolete inventories	101	156
Depreciation and amortization	445	359
Debt related amortization included in interest expense	268	163
Stock-based compensation	551	477
Changes in operating assets and liabilities:
Trade accounts receivable	1,795	(1,276)
Inventories	399	1,056
Prepaid expenses and other current assets	94	238
Accounts payable and other current liabilities	(1,350)	(3,240)
Accrued compensation	(1,594)	(152)
Other long-term liabilities	13	178
Net cash used in operating activities	(9,811)	(15,119)
Cash flows from investing activities:
Acquisition of property, plant and equipment	(90)	(531)
Net cash used in investing activities	(90)	(531)
Cash flows from financing activities:
Borrowings under credit facility, net	11,711
Proceeds from the sale of common stock	24,046
Payments of financing costs related to issuance of common stock	(246)
Proceeds from the exercise of stock options	76	49
Payment of debt issuance costs and other financing activities		(42)
Net cash provided by financing activities	35,587	7
Net increase (decrease) in cash and cash equivalents	25,686	(15,643)
Cash and cash equivalents, beginning of period	28,165	63,710
Cash and cash equivalents, end of period	53,851	48,067
Supplemental Disclosure of Cash Flow Information:
Income Taxes Paid
Interest Paid	622	294
Acquisition of property, plant and equipment accrued not paid	$ 96	$ 51

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2017	10,849,000
Balance at Dec. 31, 2017	$ 11	$ 125,999	$ (77,836)	$ (1)	$ 48,173
Issuance of common stock, net of issuance costs of $2,190 (in shares)	3,249,000
Issuance of common stock, net of issuance costs of $2,190	$ 3	23,797			23,800
Issuance of common stock warrants		455			$ 455
Option exercises (in shares)	11,000				11,404
Option exercises		76			$ 76
Restricted stock issued, net of stock forfeited (in shares)	38,000
Restricted stock issued, net of stock forfeited
Stock-based compensation		551			551
Unrealized holding period gain (loss)				1	1
Net loss			(10,533)		(10,533)
Balance (in shares) at Mar. 31, 2018	14,147,000
Balance at Mar. 31, 2018	$ 14	$ 150,878	$ (88,369)		$ 62,523

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Additional Paid-in Capital [Member]
Stock issuance costs	$ 2,190

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations first In March 2016, Basis of Presentation 270, Interim Reporting 10 10 X. not not may Liquidity and Capital Resources first 2018, twelve 6, no may may not may may no Use of Estimates Inventories first first not Write-downs of excess and obsolete inventories were $0.1 $0.2 first 2018 2017, may Goodwill Valuation – December 31, may not first 360 10, Impairment and Disposal of Long-Lived Assets December 31, 2017 not not March 31, 2018 first 2018, first Impairment of Long-Lived Assets may not not, not 50 Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. The projected cash flows for each asset or asset group considers multiple factors, including current revenue from existing customers, proceeds from the sale of the asset or asset group and expected profit margins giving consideration to historical and expected margins. If the carrying value is not no not first 2018 first 2018 Concentration of Credit Risk No 10% 2018 2017. No 10% March 31, 2018 December 31, 2017. may 11 Warranty Reserve Subsequent Events

Note 2 - Revenue From Contracts

Note 2 - Revenue From Contracts With Customers	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	2. REVENUE FROM CONTRACTS WITH CUSTOMERS The Company adopted ASC 606, Revenue From Contracts With Customers January 1, 2018 not 606 not 2018 606 2017 605, Revenue Recognition 605 606 606, five 1 Identify the contract (s) with a customer 2 Identify the performance obligations in the contract - third not 3 Determine the transaction price - not 4 Allocate the transaction price to the performance obligations in the contract - not 5 Recognize revenue when ( or as ) the Company satisfies a performance obligation - Disaggregated Revenue - Revenue Streams & Timing of Revenue Recognition The Company’s most significant revenue streams include (i) product sales, consisting of Nuvectra’s Algovita and NeuroNexus’s neural interface systems and (ii) development and engineering service revenue. Below describes the nature of the Company’s disaggregated revenue streams. Also see Note 11, Product Sales Our product sales revenues include sales of Algovita and neural interface systems and components to the neuroscience and clinical markets. Contracts may one $10.1 first 2018. Algovita - Generally, Algovita product sales are made through the Company’s trained personnel when the Company has the obligation to perform the initial programming and stimulation which occurs on the same day as the implementation. For these customers, the products and the programming and stimulation services are not no Neural interface systems and components – Each component is a separate distinct performance obligation. The customer obtains control of the individual components upon shipment, and therefore revenue is recognized at such point in time. Shipping and handling costs – Costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues. Warranty - The Company provides a standard warranty against defects but does not Significant judgments - The Company’s contracts with customers often include promises to transfer multiple products to a customer. Determining whether the promises are considered distinct performance obligations that should be accounted for separately versus together may not Development and Engineering Service Revenue The Company’s development services are typically provided on a fixed-fee basis. Service revenue is recognized over time as the services are performed using an input method, on a cost-to-cost basis. In 2017 2018, one not $0.5 first 2018. not Significant judgments - The Company’s contracts with customers often include promises to transfer multiple products to a customer. Determining whether the promises are considered distinct performance obligations that should be accounted for separately versus together may not The Company’s service revenue is recognized over time using an input method based on costs incurred. As such, estimating the total costs to be incurred and progress to completion on the contract requires significant judgment. Management uses historical experience, project plans and an assessment of the risks and uncertainties inherent in the arrangements to establish these estimates. Various uncertainties may may not Transaction Price Allocated to Future Performance Obligations ASC 606 not one not March 31, 2018, $1.9 12 18 Contract Balances Timing of revenue recognition may not. 30 Revenue recognized during the first 2018 $0.1 no first 2018 three March 31, 2018, no Costs to Obtain and Fulfill a Contract The Company has elected to apply the practical expedient and recognize the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one one January 1, 2018 March 31, 2018, one Certain NeuroNexus contracts may no January 1, 2018 March 31, 2018.

Note 3 - Intangible Assets

Note 3 - Intangible Assets	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	3. INTANGIBLE ASSETS Intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Net Carrying Amount At March 3 1 , 201 8 Technology and patents $ 1,058 $ (659 ) $ 399 Customer lists 1,869 (915 ) 954 Total intangible assets $ 2,927 $ (1,574 ) $ 1,353 At December 3 1 , 201 7 Technology and patents $ 1,058 $ (624 ) $ 434 Customer lists 1,869 (875 ) 994 Total intangible assets $ 2,927 $ (1,499 ) $ 1,428 Aggregate intangible asset amortization expense is classified as follows (in thousands): Three Months Ended March 31, 2018 March 31, 2017 Cost of sales $ 35 $ 32 Selling, general and administrative expenses 40 40 Total intangible asset amortization expense $ 75 $ 72 Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands): Estimated Amortization Expense Remainder of 2018 $ 223 2019 293 2020 209 2021 194 2022 108 Thereafter 326 Total estimated amortization expense $ 1,353

Note 4 - Accrued Liabilities

Note 4 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4 . Accrued Liabilities Accrued liabilities consisted of the following (in thousands): At March 3 1 , 201 8 December 3 1 , 201 7 Inventory purchases $ 3,209 $ 5,825 Regulatory, clinical and quality 468 358 Deferred revenue 383 335 Sales and marketing 346 321 Interest 298 199 Research and development 238 164 Operations engagement fee 200 200 Warranty reserve 200 195 Legal 180 358 Sales and use tax 121 145 Information technology system and infrastructure implementations 62 114 Insurance - 127 Accrued other 733 486 Total accrued liabilities $ 6,438 $ 8,827

Note 5 - Employee Benefit Plans

Note 5 - Employee Benefit Plans	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	5 . EMPLOYEE BENEFIT PLANS Nuvectra Corporation 2016 2016 “2016 may may 2016 2016 1,963,614. During the three March 31, 2018, 26,716 2016 2016 first 2018 $0.6 During the three March 31, 2017, 112,300 2016 2016 three March 31, 2017 $0.4 Stock-Based Compensation three $0.1 first 2017. no first 2018. The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended March 31, 2018 March 31, 2017 Stock options $ 206 $ 171 Restricted stock and restricted stock units 345 306 Total stock-based compensation expense $ 551 $ 477 Three Months Ended March 31, 2018 March 31, 2017 Selling, general and administrative expense $ 473 $ 442 Research, development and engineering costs, net 78 35 Total stock-based compensation expense $ 551 $ 477 The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model with weighted-average assumptions based on the grant date. The weighted average fair value and assumptions used to value options granted under the 2016 Three Months Ended March 31, 2018 March 31, 2017 Weighted average fair value $ 5.92 $ 3.38 Risk-free interest rate 2.60 % 2.17 % Expected volatility 66 % 55 % Holding period (in years) 6 6 Expected dividend yield — % — % The following table summarizes the stock option activity during the first 2018: Number of Time-Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2017 870,820 $ 6.78 Granted 23,444 9.66 Exercised (11,404 ) 6.69 Forfeited or expired (21,873 ) 9.43 Outstanding at March 31, 2018 860,987 $ 6.79 7.41 $ 5,366 Exercisable at March 31, 2018 433,054 $ 6.56 6.10 $ 2,800 The Company received proceeds totaling $76 11,404 first 2018. The following table summarizes the restricted stock and restricted stock unit activity during the first 2018: Time-Vested Activity Weighted Average Fair Value Non-vested at December 31, 2017 429,005 $ 6.88 Granted 3,272 12.99 Vested (38,299 ) 8.25 Forfeited (40,655 ) 7.45 Non-vested at March 31, 2018 353,323 $ 6.87 Nuvectra Bonus Plan first 2018 2017 $0.4 $0.7 Defined Contribution Plans 401 401 1986, 401 first 2018 25% 6% $0.1 first 2018 2017.

Note 6 - Debt

Note 6 - Debt	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	6 . DEBT Long-term debt is comprised of the following (in thousands): At March 3 1 , 201 8 December 3 1 , 201 7 Term loan $ 43,100 $ 29,631 Deferred financing fees (893 ) (962 ) Discount on debt (3,798 ) (1,994 ) Total debt 38,409 26,675 Less current portion of long-term debt - 789 Total long-term debt $ 38,409 $ 25,886 Credit Facility March 2016 February 2017 February 2018 ( $45 $27.5 $27.5 $12.5 February 2018, $5 six $25 March 31, 2019 sixty no may The Term Loans bear interest at a floating rate equal to the prime rate plus 4.15%, 8.65%. March 31, 2018 8.65%. March 2020 30 September 1, 2022, 7.75% As a condition to the lenders’ funding the loans under the Credit Facility, concurrently with the initial funding of the initial Term Loan A Commitment on March 18, 2016 $15 56,533 113,066 $5.97 March 18, 2026. $1.5 $0.2 As a condition to the lenders’ funding the loans under the Credit Facility, concurrently with the funding under the initial Term Loan B Commitment on September 28, 2017 $12.5 two 22,844 45,688 $12.31 September 28, 2027. February 14, 2017, $0.04 $0.4 As a condition to the lenders’ funding the new Term Loan A and Term Loan B under the February 2018 two 30,245 60,490 $9.30 February 18, 2028. $0.5 first 2018, Upon the funding of the Term Loan C Commitment, Oxford Finance LLC and SVB Financial Group will each be entitled to additional warrants for the purchase of Nuvectra common stock. The number of shares under each warrant will be equal to the amount of the term loan made by each lender multiplied by 4.50% March 31, 2018 $0.1 not 10 In connection with the February 2018 $40 $27.5 $0.8 second 5% $1.3 3% February 2019, 2% February 2020, 1% The Loans are secured by a first The Credit Facility contains customary representations and warranties, reporting and other covenants for credit facilities of this kind including prohibitions on the payment of cash dividends on the Company’s capital stock and restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. The Company is subject to a quarterly financial covenant requiring the Company to achieve specified minimum consolidated product revenues. As of March 31, 2018, Deferred Financing Fees – At December 31, 2017 $ 962 Additions during the period - Amortization during the period (69 ) At March 31, 2018 $ 893 In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2015 03, 835 30

Note 7 - Income Taxes

Note 7 - Income Taxes	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7 . INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities. The Company records a valuation allowance when it is “more likely than not” not Pursuant to the terms of the tax matters agreement entered into with Integer at the time of the Spin-off, until March 14, 2018, one 30% 35%

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8 . COMMITMENTS AND CONTINGENCIES Litigation – not no not On September 19, 2017, three No Purchase Commitments 2018 March 31, 2018, no 2018 $1.8 Operating Leases first 2018, one March 2023. Minimum future estimated annual operating lease payments as of March 31, 2018 2018 (remaining 9 months) $ 531 2019 720 2020 732 2021 745 2022 619 Thereafter 85 Total estimated operating lease payments $ 3,432

Note 9 - Earnings (Loss) Per Sh

Note 9 - Earnings (Loss) Per Share ("EPS")	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	9. EARNINGS (LOSS) PER SHARE (“EPS”) Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is equal to basic net loss per share as the Company had no The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts): Three Months Ended March 31, 2018 March 3 1 , 201 7 Basic net loss per share: Net loss $ (10,533 ) $ (13,122 ) Weighted average common shares outstanding 12,509 10,335 Basic net loss per share $ (0.84 ) $ (1.27 ) Diluted net loss per share: Net loss $ (10,533 ) $ (13,122 ) Weighted average common shares outstanding 12,509 10,335 Dilutive stock options, restricted stock and restricted stock units - - Weighted average common shares outstanding – assuming dilution 12,509 10,335 Diluted net loss per share $ (0.84 ) $ (1.27 ) Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive 1,377 1,581

Note 10 - Fair Value Measuremen

Note 10 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	1 0 . FAIR VALUE MEASUREMENTS The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. As of March 31, 2018, 2 Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). The Company has categorized its warrants measured at fair value on a recurring basis in Level 3 3 first 2018 Balance at December 31, 2017 $ 400 Loss on fair value of warrant liability 55 Reclassification of warrant liability to equity upon issuance of warrants (455 ) Fair value of warrant liability issued in 2018 109 Gain on fair value of warrant liability (15 ) At March 31, 2018 $ 94 As discussed in Note 6, February 2018, $0.1 The Company’s investments in marketable securities primarily consist of investments in debt securities, which are classified as Cash and Cash Equivalents on the consolidated balance sheet because of their original maturities of three The fair values of marketable securities were estimated using the market approach using prices and other relevant information generated by market transactions involving identical or comparable assets. The Company uses quoted market prices in active markets or quoted market prices in markets that are not March 31, 2018, $43.4 three Marketable securities, measured at fair value, by level within the fair value hierarchy were as follows (in thousands): March 3 1 , 201 8 Fair Value Hierarchy Cost Unrealized Gain Fair Value Cash Level 1 $ 18,136 $ - $ 18,136 Government Level 1 3,995 - 3,995 Financial Level 2 10,337 - 10,337 Industrial Level 2 10,888 - 10,888 Total $ 43,356 $ - $ 43,356 December 3 1 , 201 7 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 7,336 $ - $ 7,336 Government Level 1 1,499 - 1,499 Financial Level 2 3,799 (1 ) 3,798 Industrial Level 2 8,649 - 8,649 Total $ 21,283 $ (1 ) $ 21,282 Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows: Long-lived Assets 1 first 2018 2017, no Goodwill not December 31, 1 first 2018 2017, no Warrants 10 March 31, 2018 Risk-free interest rate 2.87 % Expected volatility 65 % Contractual term (in years) 10 Dividend yield - %

Note 11 - Business Segment, Geo

Note 11 - Business Segment, Geographic and Concentration Risk Information	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Segment Reporting, Geographical, and Concentration Risk Disclosure [Text Block]	1 1 . BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION The Company has two two Nuvectra is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. Algovita is the Company’s first second first NeuroNexus designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Revenues includes sales of neural interface technology, components and systems to the neuroscience and clinical markets. An analysis and reconciliation of the Company’s product lines, business segments and geographic information to the respective information in the consolidated financial statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped or services are rendered (in thousands): Three Months Ended March 31, 2018 March 3 1 , 201 7 Product line sales: Algovita $ 9,081 $ 3,387 Neural interface components and systems 1,037 1,201 Development and engineering service 456 452 Total sales $ 10,574 $ 5,040 Three Months Ended March 31, 2018 March 3 1 , 201 7 Business segment sales: Nuvectra $ 9,537 $ 3,839 NeuroNexus 1,037 1,201 Total sales $ 10,574 $ 5,040 Three Months Ended March 31, 2018 March 31, 2017 Segment (loss) income from operations: Nuvectra $ (9,655 ) $ (12,605 ) NeuroNexus 8 56 Total segment loss from operations (9,647 ) (12,549 ) Unallocated operating expenses — — Operating loss (9,647 ) (12,549 ) Unallocated other expense, net (873 ) (573 ) Loss before provision for income taxes $ (10,520 ) $ (13,122 ) All of the Company’s long-lived tangible assets are located in the United States.

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	1 2 . related party transactions On March 14, 2016, Employee Benefit Plans 5 Supply Agreement

Note 13 - Recently Issued Accou

Note 13 - Recently Issued Accounting Standards	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	1 3 . RECENTLY ISSUED ACCOUNTING STANDARDS In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB to determine the potential impact they may not not Recently Adopted in 2018 In May 2017, 2017 09, Compensation-Stock Compensation (Topic 718 2017 09 2017 09, not 2017 09 2017 09 not In January 2017, 2017 01, Business Combinations (Topic 805 Clarifying the Definition of a Business 2017 01 not not not 2017 01 2017 01 not In August 2016, 2016 15, Statement of Cash Flows (Topic 230 2016 15 eight 2016 15 not In January 2016, 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities 2016 01 not In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09 606 2014 09 January 1, 2018 not 2014 09 not January 1, 2018 March 31, 2018. 2, Not In February 2016, 2016 02, Leases , 2016 02 2016 02 December 15, 2018 (

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Nature of Operations [Policy Text Block]	Nature of Operations first In March 2016,
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation 270, Interim Reporting 10 10 X. not not may
Liquidity and Capital Resources [Policy Text Block]	Liquidity and Capital Resources first 2018, twelve 6, no may may not may may no
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Inventory, Policy [Policy Text Block]	Inventories first first not Write-downs of excess and obsolete inventories were $0.1 $0.2 first 2018 2017, may
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Valuation – December 31, may not first 360 10, Impairment and Disposal of Long-Lived Assets December 31, 2017 not not March 31, 2018 first 2018, first
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets may not not, not 50 Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. The projected cash flows for each asset or asset group considers multiple factors, including current revenue from existing customers, proceeds from the sale of the asset or asset group and expected profit margins giving consideration to historical and expected margins. If the carrying value is not no not first 2018 first 2018
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk No 10% 2018 2017. No 10% March 31, 2018 December 31, 2017. may 11
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve
Subsequent Events, Policy [Policy Text Block]	Subsequent Events

Note 3 - Intangible Assets (Tab

Note 3 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Gross Carrying Amount Accumulated Amortization Net Carrying Amount At March 3 1 , 201 8 Technology and patents $ 1,058 $ (659 ) $ 399 Customer lists 1,869 (915 ) 954 Total intangible assets $ 2,927 $ (1,574 ) $ 1,353 At December 3 1 , 201 7 Technology and patents $ 1,058 $ (624 ) $ 434 Customer lists 1,869 (875 ) 994 Total intangible assets $ 2,927 $ (1,499 ) $ 1,428
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Three Months Ended March 31, 2018 March 31, 2017 Cost of sales $ 35 $ 32 Selling, general and administrative expenses 40 40 Total intangible asset amortization expense $ 75 $ 72
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated Amortization Expense Remainder of 2018 $ 223 2019 293 2020 209 2021 194 2022 108 Thereafter 326 Total estimated amortization expense $ 1,353

Note 4 - Accrued Liabilities (T

Note 4 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	At March 3 1 , 201 8 December 3 1 , 201 7 Inventory purchases $ 3,209 $ 5,825 Regulatory, clinical and quality 468 358 Deferred revenue 383 335 Sales and marketing 346 321 Interest 298 199 Research and development 238 164 Operations engagement fee 200 200 Warranty reserve 200 195 Legal 180 358 Sales and use tax 121 145 Information technology system and infrastructure implementations 62 114 Insurance - 127 Accrued other 733 486 Total accrued liabilities $ 6,438 $ 8,827

Note 5 - Employee Benefit Pla24

Note 5 - Employee Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	Three Months Ended March 31, 2018 March 31, 2017 Stock options $ 206 $ 171 Restricted stock and restricted stock units 345 306 Total stock-based compensation expense $ 551 $ 477 Three Months Ended March 31, 2018 March 31, 2017 Selling, general and administrative expense $ 473 $ 442 Research, development and engineering costs, net 78 35 Total stock-based compensation expense $ 551 $ 477
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2018 March 31, 2017 Weighted average fair value $ 5.92 $ 3.38 Risk-free interest rate 2.60 % 2.17 % Expected volatility 66 % 55 % Holding period (in years) 6 6 Expected dividend yield — % — %
Restricted Stock and RSU's [Member]
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Time-Vested Activity Weighted Average Fair Value Non-vested at December 31, 2017 429,005 $ 6.88 Granted 3,272 12.99 Vested (38,299 ) 8.25 Forfeited (40,655 ) 7.45 Non-vested at March 31, 2018 353,323 $ 6.87
Employee Stock Option [Member]
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Number of Time-Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2017 870,820 $ 6.78 Granted 23,444 9.66 Exercised (11,404 ) 6.69 Forfeited or expired (21,873 ) 9.43 Outstanding at March 31, 2018 860,987 $ 6.79 7.41 $ 5,366 Exercisable at March 31, 2018 433,054 $ 6.56 6.10 $ 2,800

Note 6 - Debt (Tables)

Note 6 - Debt (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	At March 3 1 , 201 8 December 3 1 , 201 7 Term loan $ 43,100 $ 29,631 Deferred financing fees (893 ) (962 ) Discount on debt (3,798 ) (1,994 ) Total debt 38,409 26,675 Less current portion of long-term debt - 789 Total long-term debt $ 38,409 $ 25,886
Schedule of Debt Issuance Costs [Table Text Block]	At December 31, 2017 $ 962 Additions during the period - Amortization during the period (69 ) At March 31, 2018 $ 893

Note 8 - Commitments and Cont26

Note 8 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2018 (remaining 9 months) $ 531 2019 720 2020 732 2021 745 2022 619 Thereafter 85 Total estimated operating lease payments $ 3,432

Note 9 - Earnings (Loss) Per 27

Note 9 - Earnings (Loss) Per Share ("EPS") (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2018 March 3 1 , 201 7 Basic net loss per share: Net loss $ (10,533 ) $ (13,122 ) Weighted average common shares outstanding 12,509 10,335 Basic net loss per share $ (0.84 ) $ (1.27 ) Diluted net loss per share: Net loss $ (10,533 ) $ (13,122 ) Weighted average common shares outstanding 12,509 10,335 Dilutive stock options, restricted stock and restricted stock units - - Weighted average common shares outstanding – assuming dilution 12,509 10,335 Diluted net loss per share $ (0.84 ) $ (1.27 ) Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive 1,377 1,581

Note 10 - Fair Value Measurem28

Note 10 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Balance at December 31, 2017 $ 400 Loss on fair value of warrant liability 55 Reclassification of warrant liability to equity upon issuance of warrants (455 ) Fair value of warrant liability issued in 2018 109 Gain on fair value of warrant liability (15 ) At March 31, 2018 $ 94
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	March 3 1 , 201 8 Fair Value Hierarchy Cost Unrealized Gain Fair Value Cash Level 1 $ 18,136 $ - $ 18,136 Government Level 1 3,995 - 3,995 Financial Level 2 10,337 - 10,337 Industrial Level 2 10,888 - 10,888 Total $ 43,356 $ - $ 43,356 December 3 1 , 201 7 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 7,336 $ - $ 7,336 Government Level 1 1,499 - 1,499 Financial Level 2 3,799 (1 ) 3,798 Industrial Level 2 8,649 - 8,649 Total $ 21,283 $ (1 ) $ 21,282
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Risk-free interest rate 2.87 % Expected volatility 65 % Contractual term (in years) 10 Dividend yield - %

Note 11 - Business Segment, G29

Note 11 - Business Segment, Geographic and Concentration Risk Information (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended March 31, 2018 March 3 1 , 201 7 Product line sales: Algovita $ 9,081 $ 3,387 Neural interface components and systems 1,037 1,201 Development and engineering service 456 452 Total sales $ 10,574 $ 5,040
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended March 31, 2018 March 3 1 , 201 7 Business segment sales: Nuvectra $ 9,537 $ 3,839 NeuroNexus 1,037 1,201 Total sales $ 10,574 $ 5,040 Three Months Ended March 31, 2018 March 31, 2017 Segment (loss) income from operations: Nuvectra $ (9,655 ) $ (12,605 ) NeuroNexus 8 56 Total segment loss from operations (9,647 ) (12,549 ) Unallocated operating expenses — — Operating loss (9,647 ) (12,549 ) Unallocated other expense, net (873 ) (573 ) Loss before provision for income taxes $ (10,520 ) $ (13,122 )

Note 1 - Summary of Significa30

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Inventory Write-down	$ 101	$ 156

Note 2 - Revenue From Contrac31

Note 2 - Revenue From Contracts With Customers (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Jan. 01, 2018
Revenue from Contract with Customer, Including Assessed Tax	$ 10,574	$ 5,040
Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,900
Contract with Customer, Performance Obligation Satisfied in Previous Period	0
Contract with Customer, Asset, Reclassified to Receivable	0
Capitalized Contract Cost, Net, Total	$ 0		$ 0
Minimum [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Maximum [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year 180 days
Product [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 10,118	4,588
Contract with Customer, Liability, Revenue Recognized	100
Service [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 456	$ 452

Note 3 - Intangible Assets - Am

Note 3 - Intangible Assets - Amortizing Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Gross carrying amount	$ 2,927	$ 2,927
Accumulated amortization	(1,574)	(1,499)
Net carrying amount	1,353	1,428
Patented Technology [Member]
Gross carrying amount	1,058	1,058
Accumulated amortization	(659)	(624)
Net carrying amount	399	434
Customer Lists [Member]
Gross carrying amount	1,869	1,869
Accumulated amortization	(915)	(875)
Net carrying amount	$ 954	$ 994

Note 3 - Intangible Assets - Ag

Note 3 - Intangible Assets - Aggregate Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Intangible asset amortization expense	$ 75	$ 72
Cost of Sales [Member]
Intangible asset amortization expense	35	32
Selling, General and Administrative Expenses [Member]
Intangible asset amortization expense	$ 40	$ 40

Note 3 - Intangible Assets, Net

Note 3 - Intangible Assets, Net - Future Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Remainder of 2018	$ 223
2,019	293
2,020	209
2,021	194
2,022	108
Thereafter	326
Total estimated amortization expense	$ 1,353	$ 1,428

Note 4 - Accrued Liabilities -

Note 4 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory purchases	$ 3,209	$ 5,825
Regulatory, clinical and quality	468	358
Deferred revenue	383	335
Sales and marketing	346	321
Interest	298	199
Research and development	238	164
Operations engagement fee	200	200
Warranty reserve	200	195
Legal	180	358
Sales and use tax	121	145
Information technology system and infrastructure implementations	62	114
Insurance		127
Accrued other	733	486
Total accrued liabilities	$ 6,438	$ 8,827

Note 5 - Employee Benefit Pla36

Note 5 - Employee Benefit Plans (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Proceeds from Stock Options Exercised	$ 76	$ 49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	11,404
401K Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	25.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	6.00%
Defined Contribution Plan, Cost	$ 100
Bonus Plan [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense	$ 400	700
Nuvectra Corporation 2016 Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance	1,963,614
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost, Total	$ 600	$ 400
Nuvectra Corporation 2016 Equity Incentive Plan [Member] | Restricted Stock Units and Non-Qualified Stock Options [Member] | Directors, Certain Officers and Key Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options and Options, Grants in Period	26,716	112,300
Integer Equity Incentives Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost, Total	$ 0	$ 100
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years

Note 5 - Employee Benefit Pla37

Note 5 - Employee Benefit Plans - Allocated Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Allocated share-based compensation expense	$ 551	$ 477
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	473	442
Research and Development Expense [Member]
Allocated share-based compensation expense	78	35
Employee Stock Option [Member]
Allocated share-based compensation expense	206	171
Restricted Stock and RSU's [Member]
Allocated share-based compensation expense	$ 345	$ 306

Note 5 - Employee Benefit Pla38

Note 5 - Employee Benefit Plans - Weighted Average Fair Value Assumption Used to Values Options Granted (Details) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Weighted average fair value (in dollars per share)	$ 5.92	$ 3.38
Risk-free interest rate	2.60%	2.17%
Expected volatility	66.00%	55.00%
Holding period (in years) (Year)	6 years	6 years
Expected dividend yield	0.00%	0.00%

Note 5 - Employee Benefit Pla39

Note 5 - Employee Benefit Plans - Summary of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Exercised, number of options (in shares)	(11,404)
Employee Stock Option [Member]
Outstanding, number of options (in shares)	870,820
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 6.78
Granted, number of options (in shares)	23,444
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 9.66
Exercised, number of options (in shares)	(11,404)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 6.69
Forfeited or expired, number of options (in shares)	(21,873)
Forfeited or expired, weighted average exercise price (in dollars per share) | $ / shares	$ 9.43
Outstanding, number of options (in shares)	860,987
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 6.79
Outstanding, weighted average remaining contractual life (Year)	7 years 149 days
Outstanding, aggregate intrinsic value | $	$ 5,366
Exercisable, number of options (in shares)	433,054
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 6.56
Exercisable, weighted average remaining contractual life (Year)	6 years 36 days
Exercisable, aggregate intrinsic value | $	$ 2,800

Note 5 - Employee Benefit Pla40

Note 5 - Employee Benefit Plans - Summary Restricted Stock Unit Activity (Details) - Restricted Stock and RSU's [Member]	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Nonvested (in shares) | shares	429,005
Nonvested (in dollars per share) | $ / shares	$ 6.88
Granted (in shares) | shares	3,272
Granted (in dollars per share) | $ / shares	$ 12.99
Vested (in shares) | shares	(38,299)
Vested (in dollars per share) | $ / shares	$ 8.25
Forfeited (in shares) | shares	(40,655)
Forfeited (in dollars per share) | $ / shares	$ 7.45
Nonvested (in shares) | shares	353,323
Nonvested (in dollars per share) | $ / shares	$ 6.87

Note 6 - Debt (Details Textual)

Note 6 - Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Feb. 28, 2018	Feb. 16, 2018	Sep. 28, 2017	Mar. 18, 2016	Mar. 31, 2018	Mar. 31, 2017
Debt Issuance Costs Incurred During Period
Derivative Liability, Total					100
Proceeds from Issuance of Long-term Debt, Total					11,711
Warrants in Connection with Term Loan A [Member] | Additional Paid-in Capital [Member]
Warrants and Rights Outstanding				$ 200
Warrants in Connection with Term Loan B [Member]
Debt Issuance Costs Incurred During Period			$ 40
Warrants in Connection with Term Loan B [Member] | Additional Paid-in Capital [Member]
Warrants and Rights Outstanding			$ 400
Warrants in Connection with Term Loan C [Member]
Class of Warrant or Right, Increase to Warrant, Percentage of Loan Divided by Market Value of Common Stock				4.50%
Warrants in Connection with Term Loan C [Member] | Other Noncurrent Liabilities [Member]
Derivative Liability, Total					100
Oxford Finance LLC and Silicon Valley Bank [Member]
Class of Warrant or Right, Issued During Period	60,490		45,688
Class of Warrant or Right, Issued During Period, Exercise Price	$ 9.30		$ 12.31
Oxford Finance LLC and Silicon Valley Bank [Member] | Additional Paid-in Capital [Member]
Warrants and Rights Outstanding	$ 500
Oxford Finance LLC and Silicon Valley Bank [Member] | Warrants in Connection with Term Loan A [Member]
Warrants and Rights Outstanding				$ 15,000
Class of Warrant or Right, Issued During Period				113,066
Class of Warrant or Right, Issued During Period, Exercise Price				$ 5.97
Debt Issuance Costs Incurred During Period				$ 1,500
Oxford Finance LLC [Member]
Class of Warrant or Right, Issued During Period	30,245		22,844
Oxford Finance LLC [Member] | Warrants in Connection with Term Loan A [Member]
Class of Warrant or Right, Issued During Period				56,533
Silicon Valley Bank [Member]
Class of Warrant or Right, Issued During Period	30,245		22,844
Silicon Valley Bank [Member] | Warrants in Connection with Term Loan A [Member]
Class of Warrant or Right, Issued During Period				56,533
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member]
Debt Agreement, Maximum Borrowing Capacity					$ 45,000
Debt Instrument, Interest Rate Floor					8.65%
Debt Instrument, Interest Rate During Period					8.65%
Debt Instrument, Percentage of Funded Loan Amounts due at Maturity					7.75%
Proceeds from Issuance of Long-term Debt, Total		$ 40,000
Repayments of Long-term Debt, Total		27,500
Loan Amendment Payment		$ 800
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | If Term Loan B Funded, Beginning April, 2018 [Member]
Debt Instrument, Number of Monthly Principal and Interest Payments					30
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Prepayment in First Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee, Amount					$ 1,300
Debt Instrument, Prepayment Fee Percentage					3.00%
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Prepayment in Second Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee, Amount					$ 1,300
Debt Instrument, Prepayment Fee Percentage					2.00%
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Prepayment After Second Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee, Amount					$ 1,300
Debt Instrument, Prepayment Fee Percentage					1.00%
Term Loans [Member] | Oxford Finance LLC and Silicon Valley Bank [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate					4.15%
Term Loan A [Member] | Oxford Finance LLC and Silicon Valley Bank [Member]
Debt Agreement, Maximum Borrowing Capacity					$ 27,500
Term Loan B [Member] | Oxford Finance LLC and Silicon Valley Bank [Member]
Debt Agreement, Maximum Borrowing Capacity			$ 12,500		$ 12,500
Term Loan C [Member]
Debt Covenant, Maximum Number of Days to Draw Loan After Revenue Requirement					60 days
Debt Instrument, Commitment Fee Percentage					5.00%
Term Loan C [Member] | Oxford Finance LLC and Silicon Valley Bank [Member]
Debt Agreement, Maximum Borrowing Capacity					$ 5,000
Debt Covenant, Minimum Product Revenue Required for Trailing Six Months					$ 25,000

Note 6 - Debt - Long-term Debt

Note 6 - Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Term loan	$ 43,100	$ 29,631
Deferred financing fees	(893)	(962)
Discount on debt	(3,798)	(1,994)
Total debt	38,409	26,675
Less current portion of long-term debt		789
Total long-term debt	$ 38,409	$ 25,886

Note 6 - Debt - Deferred Financ

Note 6 - Debt - Deferred Financing Fees (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Deferred financing fees	$ 962
Additions during the period
Amortization during the period	(69)
Deferred financing fees	$ 893

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - Greatbatch [Member] - Tax Matters Agreement [Member]	Mar. 31, 2018
Equity Issuance Limitations	30.00%
Asset Disposal Limitations	35.00%

Note 8 - Commitments and Cont45

Note 8 - Commitments and Contingencies (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Capital Expenditures Yet to Be Incurred	$ 1.8

Note 8 - Commitments and Cont46

Note 8 - Commitments and Contingencies - Minimum Future Estimated Annual Operating Lease Payments (Details) $ in Thousands	Mar. 31, 2018USD ($)
2018 (remaining 9 months)	$ 531
2,019	720
2,020	732
2,021	745
2,022	619
Thereafter	85
Total estimated operating lease payments	$ 3,432

Note 9 - Earnings (Loss) Per 47

Note 9 - Earnings (Loss) Per Share ("EPS") (Details Textual) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Weighted Average Number Diluted Shares Outstanding Adjustment, Total	0	0

Note 9 - Earnings (Loss) Per 48

Note 9 - Earnings (Loss) Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Basic net loss per share:
Net loss	$ (10,533)	$ (13,122)
Weighted average common shares outstanding (in shares)	12,509	10,335
Basic net loss per share (in dollars per share)	$ (0.84)	$ (1.27)
Diluted net loss per share:
Net loss	$ (10,533)	$ (13,122)
Weighted average common shares outstanding (in shares)	12,509	10,335
Dilutive stock options, restricted stock and restricted stock units (in shares)
Weighted average common shares outstanding – assuming dilution (in shares)	12,509	10,335
Diluted net loss per share (in dollars per share)	$ (0.84)	$ (1.27)
Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive (in shares)	1,377	1,581

Note 10 - Fair Value Measurem49

Note 10 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Derivative Liability, Total	$ 100
Debt Securities, Available-for-sale, Total	43,356		$ 21,282
Impairment of Long-Lived Assets Held-for-use	0	$ 0
Goodwill, Impairment Loss	0	$ 0
Valuation, Market Approach [Member]
Debt Securities, Available-for-sale, Total	$ 43,400

Note 10 - Fair Value Measurem50

Note 10 - Fair Value Measurements - Summary of Changes in the Fair Value of Liability Warrants (Details) - Warrant Liabilities [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Balance at December 31, 2017	$ 400
Loss on fair value of warrant liability	55
Reclassification of warrant liability to equity upon issuance of warrants	(455)
Fair value of warrant liability issued in 2018	109
Gain on fair value of warrant liability	(15)
At March 31, 2018	$ 94

Note 10 - Fair Value Measurem51

Note 10 - Fair Value Measurements - Marketable Securities Measured at Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Available-for-sale Securities, Amortized Cost Basis	$ 43,356	$ 21,283
Available-for-sale Securities, Accumulated Gross Unrealized Gain
Available-for-sale Securities	43,356	21,282
Available-for-sale Securities, Accumulated Gross Unrealized Loss		(1)
Fair Value, Inputs, Level 1 [Member] | Cash [Member]
Available-for-sale Securities, Amortized Cost Basis	18,136	7,336
Available-for-sale Securities, Accumulated Gross Unrealized Gain
Available-for-sale Securities	18,136	7,336
Available-for-sale Securities, Accumulated Gross Unrealized Loss
Fair Value, Inputs, Level 1 [Member] | US Treasury and Government [Member]
Available-for-sale Securities, Amortized Cost Basis	3,995	1,499
Available-for-sale Securities, Accumulated Gross Unrealized Gain
Available-for-sale Securities	3,995	1,499
Available-for-sale Securities, Accumulated Gross Unrealized Loss
Fair Value, Inputs, Level 2 [Member] | Financial Debt Securities [Member]
Available-for-sale Securities, Amortized Cost Basis	10,337	3,799
Available-for-sale Securities, Accumulated Gross Unrealized Gain
Available-for-sale Securities	10,337	3,798
Available-for-sale Securities, Accumulated Gross Unrealized Loss		(1)
Fair Value, Inputs, Level 2 [Member] | Industrial Debt Securities [Member]
Available-for-sale Securities, Amortized Cost Basis	10,888	8,649
Available-for-sale Securities, Accumulated Gross Unrealized Gain
Available-for-sale Securities	$ 10,888	8,649
Available-for-sale Securities, Accumulated Gross Unrealized Loss

Note 10 - Fair Value Measurem52

Note 10 - Fair Value Measurements - Fair Value Assumptions of Warrants (Details)	Mar. 31, 2018
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Assumptions of Warrants	2.87
Measurement Input, Price Volatility [Member]
Fair Value Assumptions of Warrants	65
Measurement Input, Expected Term [Member]
Fair Value Assumptions of Warrants	10
Measurement Input, Expected Dividend Rate [Member]
Fair Value Assumptions of Warrants	0

Note 11 - Business Segment, G53

Note 11 - Business Segment, Geographic and Concentration Risk Information (Details Textual)	3 Months Ended
	Mar. 31, 2018
Number of Reportable Segments	2
Number of Reporting Units	2

Note 11 - Business Segment, G54

Note 11 - Business Segment, Geographic and Concentration Risk Information - Product Line Sales (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue from Contract with Customer, Including Assessed Tax	$ 10,574	$ 5,040
Algovita [Member]
Revenue from Contract with Customer, Including Assessed Tax	9,081	3,387
Neural Interface Components and Systems [Member]
Revenue from Contract with Customer, Including Assessed Tax	1,037	1,201
Development and Engineering Services [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 456	$ 452

Note 11 - Business Segment, G55

Note 11 - Business Segment, Geographic and Concentration Risk Information - Business Segments Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue from Contract with Customer, Including Assessed Tax	$ 10,574	$ 5,040
Segment loss from operations	(9,647)	(12,549)
Unallocated operating expenses	15,413	15,178
Unallocated other expense, net	(873)	(573)
Loss before provision for income taxes	(10,520)	(13,122)
Operating Segments [Member]
Segment loss from operations	(9,647)	(12,549)
Segment Reconciling Items [Member]
Unallocated operating expenses
Nuvectra Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax	9,537	3,839
Nuvectra Segment [Member] | Operating Segments [Member]
Segment loss from operations	(9,655)	(12,605)
NeuroNexus Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax	1,037	1,201
NeuroNexus Segment [Member] | Operating Segments [Member]
Segment loss from operations	$ 8	$ 56